- A new AI-driven vaccine technology has been developed, aiming to provide broad immunity against entire families of viruses and future mutations with a single injection.
- Researchers believe this “super-antigen” approach, created using AI machine learning, could prevent future pandemics, save millions of lives and eliminate the need for lockdowns.
- A world-first Phase I human trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and DIOSynVax, demonstrated its safety and triggered an immune response against SARS-CoV-2, SARS, and related bat viruses.
- The vaccine is administered using a needle-free microfluid jet, which delivers vaccine blueprints directly into skin cells.
- Experts, including Professor Jonathan Heeney and Professor Saul Faust, hail this as a “big paradigm change” from current reactive vaccine development, offering “future-proofed” protection against emerging pathogens.
IN FULL
